1		
2		
3		
4		
5		
6		
7		
8	UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON AT SEATTLE	
10	NORTHSTAR NEUROSCIENCE, INC., a	CASE No.
11	Washington Corporation,	COMPLAINT FOR TRADEMARK
12	Plaintiff,	INFRINGEMENT, FALSE DESIGNATION OF ORIGIN,
13	V.	CANCELLATION OF REGISTRATION, AND COMMON LAW INFRINGEMENT
14	NEURONETICS, INC., a Delaware Corporation,	AND UNFAIR COMPETITION
15	Defendant.	JURY DEMAND
16		
17	Plaintiff Northstar Neuroscience, Inc. alleges as follows:	
18	PA	ARTIES
19	1. Plaintiff Northstar Neuroscience, Inc. ("Northstar") is a Washington corporation	
20	with its principal place of business at 2401 Fourth Avenue, Suite 300, Seattle, Washington	
21	98121.	
22	2. Northstar is informed and believes and on that basis alleges that defendant	
23	Neuronetics, Inc. ("Defendant" or "Neuronetics") is a Delaware corporation which maintains	
24	its principal place of business at One Great Valley Parkway, Suite 2, Malvern, Pennsylvania	
25	19355. Northstar is further informed and believes and on that basis alleges that Defendant has	
26		
	COMPLAINT - 1	DLA Piper US LLP 701 Fifth Avenue, Suite 7000 Seattle, WA 98104-7044 Tel: 206.839.4800

conducted clinical trials in Washington concerning the products at issue in this case, including in this judicial district.

NATURE OF THE CASE

3. This is an action for trademark and trade name infringement and related causes of action arising out of Defendant Neuronetics's use of the marks NEUROSTAR, NEUROSTAR TMS THERAPY, NEUROSTAR and Design, and NEUROSTAR TMS THERAPY and Design, and each of them (collectively, the "NEUROSTAR Marks"), which infringe Plaintiff's trade name and trademark NORTHSTAR NEUROSCIENCE, and each of them (collectively the "NORTHSTAR NEUROSCIENCE Mark" or "Mark"). Despite Northstar's request that Defendant Neuronetics cease or limit use of the infringing NEUROSTAR Marks, Defendant has declined to do so and has continued to use the infringing Marks in connection with products used to treat neurological or psychiatric conditions, in clear violation of Northstar's rights. Northstar seeks immediate injunctive relief to prevent Defendant from using the NEUROSTAR Marks, as well as any damages, Defendant's profits, fees, costs, and other monetary and equitable relief.

JURISDICTION AND VENUE

- 4. Plaintiff Northstar brings claims for: (i) infringement in violation of Section 32 of the Trademark Act of 1946, as amended (the "Lanham Act"), 15 U.S.C. § 1114; (ii) false designation of origin and unfair competition in violation of Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a); (iii) cancellation of registration under 15 U.S.C. § 1119; and (iv) infringement and unfair competition in violation of the common law of the state of Washington.
- 5. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. § 1338 and 1119, and has supplemental jurisdiction over the claims arising out of state law pursuant to 28 U.S.C. § 1367(a).

6. Venue in this district is proper under 28 U.S.C. § 1391(b)(1) and (2) as Northstar is informed and believes and on that basis alleges that Defendant Neuronetics has conducted business in this judicial district, including conducting clinical trials in this judicial district, and a substantial part of the events giving rise to the claims alleged occurred in this district. Northstar is further informed and believes and on that basis alleges that Defendant operates a website at www.neuronetics.com which is accessible in this judicial district and which indicates that it has conducted clinical trials at the University of Washington. *See* Exhibit B (referenced below and http://www.neuronetics.com/sites.html).

PLAINTIFF NORTHSTAR NEUROSCIENCE AND ITS NORTHSTAR NEUROSCIENCE MARK

- 7. Northstar is a medical device company that develops and provides innovative neurostimulation therapies to restore function and quality of life for people suffering from stroke and other neurological diseases and disorders, including stroke motor recovery, aphasia, tinnitus and depression. Northstar's innovative technology is designed to deliver targeted electrical stimulation to the brain, in a process referred to as cortical stimulation. Northstar has used the tradename and mark NORTHSTAR NEUROSCIENCE since at least as early as June 2004. Northstar is also the owner of a federal trademark registration for the NORTHSTAR NEUROSCIENCE Mark, which was issued on August 16, 2005 (Reg. No. 2,986,214) for "medical electrical stimulation generators and accessories for application of electrical stimulation signals to the cerebral cortex of the brain, namely medical electrodes, medical electrode applicators and medical electrode cables." Attached as Exhibit A is a true and correct copy of the registration certificate issued to Northstar from the United States Patent and Trademark ("USPTO") for the NORTHSTAR NEUROSCIENCE Mark.
- 8. By virtue of such use and registration of the NORTHSTAR NEUROSCIENCE Mark, Northstar has acquired protectable intellectual property rights in the NORTHSTAR NEUROSCIENCE Mark. Northstar has established considerable reputation and goodwill in

the NORTHSTAR NEUROSCIENCE Mark, and medical professionals, clinical trial patients, customers and potential customers and others in the industry associate the Mark with Northstar's products. Attached as Exhibit B are true and correct copies of printouts from Plaintiff Northstar's website at www.northstarneuro.com showing its Mark.

DEFENDANT'S INFRINGING ACTIVITIES

- 9. Northstar is informed and believes and on that basis alleges that Defendant Neuronetics is a medical device company that develops products for treatment of neurological and psychiatric disorders. Northstar is informed and believes and on that basis alleges that Neuronetics uses the NEUROSTAR Marks in connection with its NeuroStar TMS Therapy System which is a product or products for the treatment of major depression, and which provides stimulation to the cortex of the brain. Attached hereto as Exhibit C are printouts from the Neuronetics website at www.neuronetics.com describing this product or showing its NEUROSTAR Marks.
- 10. Northstar is informed and believes and on that basis alleges that Defendant has conducted clinical trials of its product, has given presentations about its products and related technology, and intends to sells its products to customers throughout the country, using the NEUROSTAR Marks.
- 11. Northstar is informed and believes and on that basis alleges that Defendant first began using the infringing NEUROSTAR Marks in connection with Defendant's products or services in or about May 2006 about two years after the date when Northstar first began using its NORTHSTAR NEUROSCIENCE Mark, and after Northstar had obtained a federal registration for its NORTHSTAR NEUROSCIENCE Mark. Northstar is further informed and believes and on that basis alleges that Defendant was aware or should have been aware of Northstar and its NORTHSTAR NEUROSCIENCE Mark and registration at the time that Defendant adopted and began using the infringing NEUROSTAR Marks. The parties are both

11

8

18

24

23

25 26 in the medical device field, and Northstar's federal trademark registration provided constructive notice of Northstar's rights in the NORTHSTAR NEUROSCIENCE Mark.

- 12. Northstar is informed and believes and on that basis alleges that Defendant's products are similar to Northstar's products in that both Defendant and Northstar provide products that are designed to provide stimuli to the cortex of the brain to treat psychiatric or neurological disorders. More particularly, Northstar is informed and believes and on that basis alleges that Neuronetics has done clinical trials in which a Neuronetics device is used to apply stimuli to the cortex of the brain to treat major depression, and Northstar has also done clinical trials in which a Northstar device is used to apply stimuli to the cortex of the brain to treat major depression.
- 13. Northstar is informed and believes and on that basis alleges that Defendant markets or has presented information about its products to individuals and groups in the medical field, which is the same field that Northstar is in and that Northstar targets. For example, Northstar researchers attended an American Psychiatric Association conference last year at which Neuronetics presented clinical trial results.
- 14. Defendant's use of the NEUROSTAR Marks for its products is likely to cause confusion as to association, sponsorship, endorsement, ownership, or affiliation between Defendant and Northstar, and Northstar's NORTHSTAR NEUROSCIENCE Mark, thereby infringing Northstar's rights in its NORTHSTAR NEUROSCIENCE Mark.
- 15. Northstar is informed and believes and on that basis alleges that at least one individual in the medical device industry was confused by the similarity of the NEUROSTAR Marks with Northstar's Marks, mistaking an action or announcement by the Food & Drug Administration (FDA) regarding the NEUROSTAR product as being one for Northstar's product.
- 16. In or about November 16, 2006, counsel for Northstar sent a cease and desist letter to Neuronetics requesting that Neuronetics cease using the NEUROSTAR mark and

withdraw its applications to register the mark NEUROSTAR. The parties attempted to resolve the matter, but no resolution has been reached and Neuronetics continues to use the NEUROSTAR Marks.

FIRST CLAIM FOR RELIEF Federal Trademark Infringement and Counterfeiting 15 U.S.C. § 1114

- 17. Plaintiff Northstar realleges and incorporates by reference the allegations in paragraphs 1 through 16 as if fully set forth herein.
- 18. Plaintiff's NORTHSTAR NEUROSCIENCE Mark is distinctive and Northstar has used its NORTHSTAR NEUROSCIENCE Mark to distinguish and to identify its products. Northstar has acquired substantial goodwill through the use of its NORTHSTAR NEUROSCIENCE Mark, and obtained federal registration for the Mark, as described above.
- 19. Defendant's use of the NEUROSTAR Marks in connection with Defendant's goods and/or services and related promotional activities is likely to cause confusion, mistake, or deception, and constitutes infringement of Northstar's registered NORTHSTAR NEUROSCIENCE Mark, in violation of Section 32 of the Lanham Act, 15 U.S.C. § 1114.
- 20. Northstar is informed and believes and on that basis alleges that Defendant was or should have been aware of Northstar and the NORTHSTAR NEUROSCIENCE Mark and the use thereof by Northstar to identify Northstar and its products, prior to Defendant's use of the infringing NEUROSTAR Marks.
- 21. Northstar is informed and believes and on that basis alleges that as a result of Defendant's acts of trademark infringement and unfair competition, Defendant has benefited in the marketplace, at the expense of and causing injury to Northstar.
- 22. Northstar is informed and believes and on that basis alleges that as a result of Defendant's adoption and use of the infringing NEUROSTAR Marks, Defendant is able to obtain recognition and build a reputation in the market, all to the detriment of Northstar and to the benefit, and unjust enrichment, of Defendant.

DLA Piper US LLP 701 Fifth Avenue, Suite 7000 Seattle, WA 98104-7044 | Tel: 206.839.4800

23. As a result of Defendant's unlawful conduct, Northstar has been and continue
to be substantially and irreparably harmed. If Defendant's infringement and unlawful acts are
permitted to continue, further damage and irreparable injury will be sustained by Northstar
Through such unfair acts and use of confusingly similar marks, the value of Northstar's
NORTHSTAR NEUROSCIENCE Mark will be diminished or destroyed, for which damage
Northstar cannot be adequately compensated at law. Accordingly, Northstar is entitled to
preliminary and permanent injunctive relief against Defendant, including an order enjoining
Defendant from using the NEUROSTAR Marks.

- 24. Northstar is informed and believes and on that basis alleges that Defendant has benefited from its infringement of Northstar's NORTHSTAR NEUROSCIENCE Mark, and Defendant's use of the NEUROSTAR Marks has caused or is likely to cause loss and damage to Northstar, including to its goodwill, reputation and its Mark.
- 25. Plaintiff's damages may be trebled pursuant to Section 35(a) of the Lanham Act, 15 U.S.C. § 1117(a) because, upon information and belief, Defendant's actions have been committed willfully, with intent and full knowledge of the NORTHSTAR NEUROSCIENCE Mark and Northstar's rights in the NORTHSTAR NEUROSCIENCE Mark, among other In addition, Northstar is entitled to recover Defendant's profits and reasonable royalties, if any, as well as costs of this action and reasonable attorney's fees.

SECOND CLAIM FOR RELIEF False Designation of Origin and Unfair Competition 15 U.S.C. § 1125(a)

21

22

23

26. Plaintiff Northstar realleges and incorporates by reference the allegations in paragraphs 1 through 25 as if fully set forth herein.

24 25

27. Defendant's use of the infringing NEUROSTAR Marks in connection with Defendant's goods and services and related promotional activities is likely to cause confusion, mistake, or deception as to affiliation, connection, or association with Northstar, and is also COMPLAINT - 7 DLA Piper US LLP

701 Fifth Avenue, Suite 7000 Seattle, WA 98104-7044 | Tel: 206.839.4800

likely to cause confusion as to the origin, sponsorship, or approval of Defendant's goods, services, or activities by Northstar, all in violation of Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a).

- 28. In addition, Defendant's use of the NEUROSTAR Marks constitutes a false designation of origin, false or misleading description of fact, or false or misleading representation of fact which is likely to cause confusion (including reverse confusion), mistake, or deception as to affiliation, connection, or association with Northstar, and is also likely to cause confusion as to the origin, sponsorship, or approval of Defendant's goods, services, or activities by Northstar, all in violation of Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a).
- 29. Defendant's use of the NEUROSTAR Marks has caused and will continue to cause irreparable harm for which Northstar has no adequate remedy at law, in that, among other things, (i) the ownership of the NORTHSTAR NEUROSCIENCE Mark constitutes a unique and valuable property right which has no readily determinable market value; (ii) Defendant's activities constitute a substantial interference with Northstar's goodwill and relationship with its customers, physicians and others in the medical community, partners, vendors, the general public, and the media; and (iii) Defendant's activities, and the harm resulting to Northstar, are continuing. Accordingly, Northstar is entitled to preliminary and permanent injunctive relief.
- 30. As a result of Defendant's unlawful conduct, Plaintiff has incurred damages in an amount to be proven at trial consisting of, among other things, diminution in the value of and goodwill associated with Plaintiff's NORTHSTAR NEUROSCIENCE Mark. Plaintiff's damages may be trebled pursuant to Section 35(a) of the Lanham Act, 15 U.S.C. § 1117(a) because, upon information and belief, Defendant's actions have been committed willfully, with intent and full knowledge of Northstar's rights, among other things. In addition, Northstar is entitled to recover Defendant's profits and reasonable royalties, if any, as well as costs of this action and reasonable attorney's fees.

THIRD CLAIM FOR RELIEF Cancellation of Registration 15 U.S.C. § 1119

- 31. Plaintiff Northstar realleges and incorporates by reference the allegations in paragraphs 1 through 30 as if fully set forth herein.
- 32. Northstar is informed and believes and on that basis alleges that in or about February 10, 2006, Defendant filed an application to register the mark NEUROSTAR with the USPTO in connection with products designed to stimulate the brain, specifically "transcranial magnetic stimulation devices consisting of a stimulator and a patient positioning system, namely, a chair and headset." The mark was eventually registered on December 19, 2006 (Reg. No. 3187054).
- 33. Plaintiff believes it is and will be damaged by this registration of the NEUROSTAR mark and Defendant's continued use of the mark, as alleged above, including that the NEUROSTAR mark infringes Plaintiff's NORTHSTAR NEUROSCIENCE Mark.
- 34. Pursuant to 15 U.S.C. § 1119, Plaintiff requests that this Court determine that the NEUROSTAR mark infringes or otherwise causes damage to Plaintiff and its rights in its NORTHSTAR NEUROSCIENCE Mark, and order the cancellation of USPTO Registration No. 3187054.

FOURTH CLAIM FOR RELIEF Common Law Infringement and Unfair Competition

- 35. Plaintiff Northstar realleges and incorporates by reference the allegations in paragraphs 1 through 34 as if fully set forth herein.
- 36. The foregoing acts of Defendant constitute infringement and unfair competition in violation of the common law of the state of Washington.
- 37. Defendant's use of the NEUROSTAR Marks is in violation and derogation of Northstar's common law rights in its NORTHSTAR NEUROSCIENCE Mark, and is likely to cause confusion, mistake and deception among customers and the public as to the source,

origin, sponsorship or quality of Northstar's goods and services and business, thereby causing loss, damage and injury to Northstar and the public. Defendant knew, or in the exercise of reasonable care should have known, that its infringing conduct was likely to mislead the public, and those engaged in the sale, marketing, development, purchase or distribution of products and services in the medical device industry.

- 38. Northstar is informed and believes and on that basis alleges that the foregoing conduct by Defendant has been knowing, deliberate, willful, and with the knowledge that it is likely to cause mistake or to deceive, and in disregard of Northstar's rights.
- 39. As a result of Defendant's unlawful conduct, Northstar has been and continues to be substantially and irreparably harmed. If Defendant's unfair competition and acts are permitted to continue, further damage and irreparable injury will be sustained by Northstar. Through such unfair acts and use of a confusingly similar mark, the value of Northstar's NORTHSTAR NEUROSCIENCE Mark will be diminished or destroyed, for which damage Northstar cannot be adequately compensated at law.
- 40. Northstar is informed and believes and on that basis alleges that Defendant has derived unlawful gains or benefits from its unlawful acts, as alleged above, and has caused or is likely to cause loss and damage to Northstar, including its goodwill, reputation and its Mark, in an amount as yet unknown but to be proven at trial.
- 41. Northstar has no adequate remedy at law for, and is being irreparably harmed by, Defendant's continuing violation of it rights as set forth above, and such harm will continue unless Defendant is enjoined by this Court.

REQUEST FOR RELIEF

WHEREFORE, Northstar prays for relief as follows:

1. That Defendant be adjudged to have infringed Northstar's NORTHSTAR NEUROSCIENCE Mark in violation of federal and Washington state law;

- 10 11
- 12
- 15
- 16
- 17

- 21

- 24
- 25
- 26

- 2. That Defendant be adjudged to have willfully and deliberately infringed Northstar's NORTHSTAR NEUROSCIENCE Mark in violation of federal and Washington state law;
- 3. That Defendant be adjudged to have competed unfairly with Northstar and used a false designation of origin in violation of federal and Washington state law;
- 4. That Defendant be adjudged to have willfully and deliberately used false designations of origin and competed unfairly with Northstar in violation of federal and Washington state law;
- 5. That Defendant, its officers, agents, servants, employees and all persons acting or claiming to act on its behalf under its direction or authority, and all persons acting or claiming to act in concert or in participation with it or any of them, be preliminarily and permanently enjoined and restrained from infringing Northstar's NORTHSTAR NEUROSCIENCE Mark in any manner in the promotion, clinical testing, distribution, purchase, advertising or sale of Defendant's products and services, and, in particular, from using the NEUROSTAR Marks;
- 6. That Defendant, its officers, agents, servants, employees and all persons acting or claiming to act on its behalf under its direction or authority, and all persons acting or claiming to act in concert or in participation with it or any of them, be permanently enjoined and restrained from or engaging in acts of unfair competition relating to use of the NEUROSTAR Marks in any manner, in the promotion, clinical testing, distribution, purchase, advertising or sale of Defendant's goods and services;
- 7. That Defendant be required to turn over and deliver up to the Court or to a Court-designated party during the pendency of this action all infringing materials in their custody and control (including records regarding manufacture and marketing) and all matters used to make infringing materials, as well as turn over and deliver any and all catalogues, marketing materials or labels in its possession, custody or control, or that of its owners,

1	JURY TRIAL DEMANDED	
2		
3	Pursuant to Rule 38(a) of the Federal Rules of Civil Procedure, Plaintiff demands a trial	
4	by jury of all issues properly triable of right by a jury.	
5	Dated this 7th day of March, 2007.	
6		
7	s/ Stellman Keehnel	
8	Stellman Keehnel, WSBA No. 9309 Russell Wuehler, WSBA No. 37941	
9	DLA PIPER US LLP 701 Fifth Avenue, Suite 7000	
10	Seattle, WA 98104-7044	
11	Telephone: 206.839.4800 Fax: 206.839.4801	
12	E-mail: <u>stellman.keehnel@dlapiper.com</u> russell.wuehler@dlapiper.com	
13	Attorneys for Plaintiff Northstar Neuroscience, Inc.	
14	SE\9094153.1 350863-900219	
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
	COMPLAINT - 13 DLA Piper US LLP	